Consensus $4.83. Narrows FY25 revenue view to $4.15B-$4.3B from $4.15B-$4.4B, consensus $4.23B
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)
- 3 “Strong Buy” Growth Stocks to Buy Now, 8/5/2025, According to Analysts
- These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis
- Jazz Pharmaceuticals’ Zanidatamab Study: A Potential Game-Changer in Breast Cancer Treatment
- JAZZ Earnings this Week: How Will it Perform?